{
    "clinical_study": {
        "@rank": "131000", 
        "acronym": "RIMECARD", 
        "arm_group": [
            {
                "arm_group_label": "ucMSC", 
                "arm_group_type": "Experimental", 
                "description": "Umbilical cord derived mesenchymal are injected intravenously  to Patients."
            }, 
            {
                "arm_group_label": "Controls", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous placebo solution are administrated to Patients."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and clinical effectiveness of umbilical\n      cord mesenchymal cells transplanted by intravenous infusion in patients with heart failure."
        }, 
        "brief_title": "Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Dilated Cardiomyopathy", 
        "condition_browse": {
            "mesh_term": [
                "Cardiomyopathy, Dilated", 
                "Heart Diseases", 
                "Heart Failure", 
                "Cardiomyopathies"
            ]
        }, 
        "detailed_description": {
            "textblock": "Phase I-II Clinical Trial - Safety and efficacy of umbilical cord derived mesenchymal stem\n      cells (ucMSC) in patients with heart failure Randomized, double blind, controlled\n      prospective study in patients with compensated heart failure in dilated phase.\n\n      Thirty patients will be selected, who will undergo a strict 3-month followup of ventricular\n      function before being sequentially randomized into two groups: the first group of 15\n      patients will receive a sole injection of ucMSC and the remaining 15 patients will comprise\n      the control group.\n\n      Every patient will maintain their standard treatment of heart failure, with maximum\n      tolerated dosage without side effects.\n\n      The day of infusion will be considered day zero. From that moment, followup will be divided\n      into 0-3, 3-6, and 6-12 months.\n\n      Clinical results will be analyzed after completion of 12 months of followup."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptomatic heart failure patients in dilated stages\n\n          -  Etiologies: dilated cardiomyopathy, chronic hypertensive cardiopathy in dilated\n             stage, chronic coronary cardiopathy in dilated stage\n\n          -  Ejection fraction \u2264 40%.\n\n          -  Patients who are stable under optimal medical treatment for a period of at least 3\n             months prior to randomization\n\n        Exclusion Criteria:\n\n          -  Severe or persistent heart failure\n\n          -  Recurrent myocardial ischemia\n\n          -  Uncontrolled ventricular tachycardia\n\n          -  Malignant disease (life expectancy of less than one year)\n\n          -  Manifest ventricular asynchrony\n\n          -  Hematologic disease\n\n          -  Recent cerebrovascular disease\n\n          -  Recent acute coronary syndrome\n\n          -  Serum creatinine >2.26 mg/dL (200 umol/L)\n\n          -  Atrial fibrillation without heart rate control in the last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739777", 
            "org_study_id": "UANDES-C4C", 
            "secondary_id": "CORFO-11IEI-9766"
        }, 
        "intervention": [
            {
                "arm_group_label": "ucMSC", 
                "description": "1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma", 
                "intervention_name": "ucMSC", 
                "intervention_type": "Biological", 
                "other_name": "Umbilical Cord Mesenchymal Stem Cells"
            }, 
            {
                "arm_group_label": "Controls", 
                "description": "Autologous Serum will administrated as placebo", 
                "intervention_name": "Controls", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Heart Failure", 
            "Coronary Heart Disease", 
            "Adult Stem Cells", 
            "Umbilical Progenitor Cells", 
            "Umbilical Cord Stem Cells Allogenic", 
            "Left Ventricular Function", 
            "Intravenous Injection"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "link": {
            "description": "Universidad de los Andes.", 
            "url": "http://www.uandes.cl/"
        }, 
        "location": {
            "contact": {
                "email": "jbartolucci@gmail.com", 
                "last_name": "JORGE BARTOLUCCI, MD", 
                "phone": "56-2-29132958"
            }, 
            "contact_backup": {
                "email": "fjverdugo@miuandes.cl", 
                "last_name": "FERNANDO J VERDUGO, MD", 
                "phone": "56-2-2421219"
            }, 
            "facility": {
                "address": {
                    "city": "Santiago de Chile", 
                    "country": "Chile"
                }, 
                "name": "Universidad de los Andes"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology", 
        "other_outcome": [
            {
                "description": "The cytokine profile we can determinate is  Interleukin 1 Beta(IL-1b),Interleukin 6 (IL-6), soluble receptor TNF (TNFRs), tumor necrosis factor(TNF), Interleukin 10 (IL-10), Transforming Growth Factor  beta (TGFb),  Interferon-gamma (IFNg),Interleukin 17A (IL-17A),Interleukin-4(IL-4) by multiflex flow cytometer.", 
                "measure": "Measures of anti & pro inflammatory cytokines  profile", 
                "safety_issue": "No", 
                "time_frame": "0-15-90 days"
            }, 
            {
                "description": "Measures by specific questionnaire of quality of life:\nMinnesota Living with Heart Failure Questionnaire (MLHFQ). Kansas, City Cardiomyopathy Questionnaire (KCCQ)", 
                "measure": "Change in quality of life", 
                "safety_issue": "No", 
                "time_frame": "0-6-12 months"
            }
        ], 
        "overall_contact": {
            "email": "jbartolucci@gmail.com", 
            "last_name": "Jorge G Bartolucci, Dr.", 
            "phone": "56-2-2913 29 58"
        }, 
        "overall_contact_backup": {
            "email": "fjverdugo@miuandes.cl", 
            "last_name": "Fernando J Verdugo, Dr.", 
            "phone": "56-2-22421219"
        }, 
        "overall_official": {
            "affiliation": "Universidad de los Andes", 
            "last_name": "Jorge Bartolucci, Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Chile: Comit\u00e9 de \u00c9tica Cient\u00edfico", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022 Change in global left ventricular ejection fraction", 
            "safety_issue": "No", 
            "time_frame": "3, 6, 12 months"
        }, 
        "reference": {
            "PMID": "19958962", 
            "citation": "Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB Jr, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009 Dec 8;54(24):2277-86."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739777"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidad Los Andes", 
            "investigator_full_name": "Jorge Bartolucci", 
            "investigator_title": "Medical director of Celular Therapy", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "\u2022 Change in functional capacity measured in O2 consumption", 
                "safety_issue": "No", 
                "time_frame": "0, 3, 6, 12 months"
            }, 
            {
                "measure": "\u2022 Occurrence of major adverse cardiac event", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "\u2022 Change in high sensitivity C-reactive protein (hs CRP)", 
                "safety_issue": "No", 
                "time_frame": "0, 3, 6, 12 months"
            }, 
            {
                "measure": "\u2022 Reduction in level of B-type natriuretic peptide (BNP)", 
                "safety_issue": "No", 
                "time_frame": "0, 3, 6, 12 months"
            }
        ], 
        "source": "Universidad Los Andes", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universidad Los Andes", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}